A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms SOPRANO
- Sponsors Actelion Pharmaceuticals
- 14 Feb 2018 Planned End Date changed from 1 May 2018 to 1 Jul 2021.
- 14 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2020.
- 21 Nov 2017 Planned number of patients changed from 64 to 78.